SUMMARY. In addition to their desired anticancer effects, most cancer treatments may also cause transient toxicity, permanent organ damage, or death. A critical question in comparing an experimental treatment to a standard is haw much increase in an adverse event rate is an acceptable trade-off for achieving a targeted improvement in efficacy, or vice versa. We consider settings where one may characterize patient outcome as a bivariate (efficacy, safety) variable and quantify treatment effect as a corresponding two-dimensional parameter. A set of target parameters, each representing a clinically meaningful improvement over the standard, are elicited from the physician. Each target is a two-dimensional generalization of the usual onedimensional shift parameter. We define the alternative hypothesis in the two-dimensional effect space as the convex hull of the sets of parameters that are at least as desirable as each target point. The rejection region is obtained by shifting the alternative toward (0,O) to achieve a given type I error, with sample size computed to achieve a given power at the targets. The method is illustrated by application to two cancer chemotherapy trials.
Introduction
An inherent problem in cancer therapeutics is that, in addition to their desired anticancer effects, treatments may also cause transient toxicity, permanent organ damage, or death. In many oncology trials, an experimental treatment may have not only a greater efficacy than the standard therapy but also a higher adverse event rate. For example, a higher chemotherapy dose for treatment of soft tissue sarcoma increases the probabilities of both tumor shrinkage and life-threatening toxic effects on the kidneys and nervous system. In chemotherapy of acute leukemia, the first goal is to achieve complete remission (CR), as this is a necessary precursor to long-term survival. Unfortunately, experimental treatments for leukemia often increase the rates of both CR and myelosuppression. Allogeneic bone marrow or peripheral blood stem cell transplantation, in which cells from a matched donor are infused into the patient, carries the risk of graft-versus-host disease, which may be fatal. Because the brain is thought to be a site of lung cancer metastasis, prophylactic irradiation of the brain may be prescribed for certain lung cancer patients. In this case, loss of brain function may be the price paid for a decreased risk of brain cancer.
Each of these examples illustrates the antagonistic relationship between efficacy and safety in cancer therapeutics. If the primary goal of a clinical trial is to improve efficacy by some targeted amount, then a critical question is how much of an increase in the risk of a severe adverse event is an acceptable trade-off for achieving the targeted improvement in effcacy. The analogous question is how much drop in efficacy, if any, is acceptable to achieve a targeted improvement in safety.
In this paper, we address these considerations by formiilatiiig hypotheses in terms of a multidimensional parameter characterizing efficacy and safety outcomes together, rather than regarding one as the primary endpoint and the other as the secondary. We consider a class of testing problems motivated by comparative clinical trials where the patient outconie can be characterized by a bivariate (efficacy, safety) variable and specific clinical goals can be quantified in terms of a twodimensional treatment effect parameter A = (Al, Az), where A1 accounts for efficacy and A2 for safety. We propose a geometric method for constructing two-sample tests tailored to these clinical goals. This method first requires the specification of a set of target points (1, . . . , ( K in A-space that constitute clinically meaningful improvements over the null hypothesis 0 = (0,O). The target points are elicited from the physician. Each ( is a two-dimensional generalization of the usual one-dimensional shift used to construct tests based on a single parameter. We define the alternative hypothesis in 746 this t'wo-dimensional effect space to be the convex hull of the sets of A that are at least as desirable as the target points.
The rejection region of the test, defined in terms of a consistent estimator A of A, is obtained by shifting the boundary of the alternative toward 0 to achieve a given type I error.
Sample size is computed similarly to the usual method for achieving a given power, with the important difference being that here the power figures at all K-targeted alternatives are considered.
In recent years, there have been many proposals for constructing tests based on multiple outcomes in clinical trials (O'Brien, 1984; Wei and Lachin, 1984; Pocock, Geller, and Tsiatis, 1987; Tang, Gnecco, and Geller, 1989; Wei, Lin, and Weissfeld, 1989; Wei, Su, and Lachin, 1990; Su and Lachin, 1992) . Tests based on the consideration of the two-dimensional structure of the space of parameters characterizing safety and efficacy have been proposed by Jennison and Turnbull (1993) for randomized trials and, for single-arm phase I1 trials, by Bryant and Day (1995) and Petroni (1995, 1996) . We are similarly motivated by the geometry of the two-dimensional parameter space. Cook and Farewell (1994) and Cook (1994 Cook ( , 1996 dealt with the sequential testing problem for safety and efficacy by defining bivariate error spending functions, thereby extending the fundamental idea of Lan and DeMets (1983) . Williams (1996) addressed the sequential monitoring problem in the case of multiple time-to-event outcomes. A general approach to group-sequential trials accommodating multivariate outcomes and covariates has been given by Jennison and Turnbull (1997) .
The remainder of the paper is organized as follows. In Section 2 , we formally define the proposed method. Numerical computation is discussed in Section 3. Section 4 presents two illustrative applications. We close with a discussion in Section 5 .
Constructing Two-Dimensional Tests
Let T and C index the experimental treatment and the standard control, respectively, and let Y1 and Y2 denote the efficacy and safety outcomes, respectively. Our method requires the specification of a two-dimensional treatment effect parameter A = (Al, A2) such that A, and A2 are real-valued T-versus-C efficacy and safety effects, respectively, with 0 = (0,O) the null point corresponding to no treatment difference. Thus, positive values of A1 and A2 correspond to superior efficacy and superior safety, respectively, with T compared with C , whereas negative values correspond to superiority of C over Our aim is to construct one-sided tests of whether T is superior to C that quantify specific clinical goals in terms of both the efficacy effect A1 and the safety effect Az. given by the dotted line in Figure 1 , to achieve a specified type I error probability a. Formally, the rejection region is To verify that the power function 4(A) = Pr{A E R(ca) 1 A} of the test is nondecreasing in each of its two arguments, we proceed similarly to Jennison and Turnbull (1993) 
is nondecreasing in each A,. Because, in general, +(el), . . . , $(&) may take on different values, in practice, the sample size 2n may be chosen either to achieve a desired power 4* at a particular target <k or to ensure that minl<k<K 4(&) 1 q5*.
We have found it useful to collaborate w i t h the physician when examining 4(<1), . . . , $(&) over a range of n, so that 61, . . . , may be appropriately modified to obtain a realistic test and sample size. Two common clinical trial settings where the method may be applied are those where both entries of Y are either binary or nonnegative valued. In the binary case, Y1 is the indicator of the efficacy event, such as 250% tumor shrinkage, whereas Y2 indicates that the adverse event, such as toxicity, did not occur. An important special case is when the occurrence of both the efficacy and adverse events is impossible, such as when the adverse event is death. Hence, there are three possible patient outcomes rather than four. The second setting typically arises when Y1 is the time to relapse or death, subject to the usual independent right censoring, and Yz quantifies safety or quality of life. For example, if the treatment is known to cause damage to a specific organ, Y2 might be a quantitative index of organ function. The distribution theory for these data structures is given in the Appendix.
Computation
For convenience and simplicity, we illustrate the method in the case of bivariate binary outcomes with the effects defined as A j = sin-1(OT,j)1/2 -sin-1(Oc,j)1/2 for j = 1,2, to stabilize the binomial variances. To facilitate presentation, we discuss parameter and trade-off values in the probability domainas we do when communicating with physicians while devel- 
Thus, R(ca) is easily obtained from a monotone search in c.
In general, the power function +(A) depends on A, n, and the correlation PA. Thus, given R(ca) and n, to com- [-1, 1 1 are feasible. We thus chose to characterize association in terms of a common odds ratio $ = $c = $ T , as this may be carried out for all 8c and 8~ corresponding to a consis-. tent probability distribution on the 2 x 2 table of outcomes. Therefore, PA generally varies with A, with the provision that PA = 0 if 11, = 1.
All numerical calculations were carried out in S-plus on ii Sun SPARC Station 20. We used the ACM Transactions on Mathematical Software Fortran algorithms 706 (Berntsen and Espelid, 1992) and 725 (Drezner, 1993) to compute approximations to bivariate normal probabilities, defined as integrals over convex sets obtained as unions of rectangles and triangles. Given a , the sample size 2n, the null OC, the targets 
Illustrations 4.1 Higher Ifosfamide Dose for Soft Tissue Sarcoma
A standard chemotherapeutic regimen for untreated metastatic soft tissue sarcoma is 10 g/m2 of ifosfamide. This dose not only achieves 250% tumor shrinkage, the efficacy outcome, in 20% of patients, but it also causes life-threatening (grade 3 or 4) nephrotoxicity or neurotoxicity in 5% of patients. Thus, by denoting the indicators of the efficacy outcome by Yl and the absence of both of these toxicities by Y2, E(YC,1, Y~J ) = ( B c , l , O~, 2 ) = (.20,.95) under this standard treatment. The clinician indicated that these efficacy and toxicity events occur independently; hence, 11, = 1. It was hypothesized that by increasing the dose to 16 g/m2, the experimental treatment might improve O C ,~ without causing too much of a decrease in O c , Z . Specifically, the three target points p1 = (.50,.85), p 2 = (.40,.90), and p3 = (.35,.95) were specified by the clinician. The first target, p1, allows a drop of 62 = -.lo in safety as a trade-off for an increase of 61 = .30 in efficacy, p2 targets the smaller increments 62 = -.05 and 61 = .20, and p3 targets the smallest clinically meaningful improvement 61 = .15, for which no drop in safety is acceptable (62 = 0). This is summarized in Table 1 as Design 1, which requires a sample size of 2n = 226 to achieve size .05 and power .80. The alternative determined by these three targets is illustrated in Figure 1 . A number of other possible designs were also considered, two of which are summarized in Table 1 as Designs 2 and 3. Under Design 2, each slippage 62 in safety is .05 larger than the corresponding value under Design 1. This difference, however, has a trivial effect on the sample size. In contrast, although the only difference between Designs 3 and 1 is that the efficacy component p s ,~ of p3 is .05 closer to 0, this more than doubles the sample size.
Chemotherapy of Acute Leukemza
Our second illustration arises from an experimental trial of the combination chemotherapy gemcitabine + cyclophosphamide (gemcy) versus the standard of cytosine arabinoside (ara-C)-based regimens for treatment of goodprognosis acute myelogenous leukemia (AML) or myelodysplastic syndrome patients. The efficacy outcome was the indicator Y1 that the patient achieved CR, whereas "toxicity" was the event that the patient either died or suffered severe myelosuppression during the first 5 weeks. Thus, Y2 was the indicator of no toxicity. The historical probabilities of these events with ara-C-based treatments were B c ,~ = .70 and B c ,~ = .62, with the odds ratio +c = 3.05. The positive association between Y1 and Y2 may be expressed in more clinical terms by the fact that the CR rate was higher among patients not experiencing toxicity, specifically Pr(Yc,l = 1 I Y c ,~ = 1) = ,790, whereas Pr(Yc%l = 1 I Y c ,~ = 0) = ,553.
Four possible designs, summarized in Table 2 and illustrated in Figure 2 , were considered for this trial. All tabulated sample sizes correspond to a = .05 and $* = .80. In Design 1, pz targets a .25 increase in B c ,~ from .62 to .87, equivalent to a drop in toxicity probability from .38 to .13, with no change in efficacy. The other target, p1, allows a drop of .05 in safety as a trade-off for an increase of .20 in efficacy. Design 2 differs from Design 1 only in that p 2 , 2 = .20 rather than .25; this increases the sample size from 334 to 436. Design 3 differs from Design 1 in that an additional third target is specified. This has the effect of greatly increasing the sample size, from 334 to 744, because the additional target is much closer to 0 , as shown in Figure 2 . Each of the Designs, 1, 2, and 3, specifies an alternative in which no drop in efficacy is desirable, regardless of how safe the experimental treatment might be. Similarly, each of these designs allows at most a small drop in safety, regardless of efficacy. In our experience constructing this type of design to compare an experimental cancer treatment with an established standard regimen, we have found that oncologists often place such absolute lower limits on efficacy, safety, or both. This attitude reflects the fact that either failing to achieve the efficacy outcome or experiencing the adverse outcome may have severe consequences for the patient. Design 4 is the most optimistic, in that each of its two targets specifies an improvement in both efficacy and safety. These four designs illustrate the general Figure 2 . gemcy versus ara-C trial in AML.
Alternative hypotheses of four designs for the phenomenon that alternatives that are closer to (0,O) require larger sample sizes. Specifically, if two alternatives are nested such that Ral c Oa2, then the test based on R2,2 requires a larger sample size. Thus, the sample size for Design 3 is larger than that for Design 1 because O,1 C Oa3. Moreover, the increase is very large because Ra3 is much closer to (0,O). This is because the power 4 ( [ ) at each target E is the volume of a bivariate normal distribution with mean 6 that is over the two-dimensional rejection region Ra -(ca,ccy), and we determine the sample size to ensure 4(E) 2 .80 at all specified targets.
To examine the sensitivity of the method to association between Yl and Y2, we computed the sample size for Design are of course more desirable. Thus, if the clinician wishes to specify not only the two-dimensional target points but also the magnitude of the third parameter, n~, 1 1 , then the sample size may be determined to achieve a given power for this three-dimensional alternative. We have used the null value +c in computations given in Tables 1 and 2 as a reasonable compromise. This is a consequence of the fact that, although (.258,-,051 ) is a reasonable two-dimensional alternative to (0,0), its second component is so close to 0 that, if considered alone, it is not a practically meaningful alternative to 0 in the A2 subspace. The point is that this two-dimensional target is determined by allowing a small drop in safety as a trade-off for a large improvement in efficacy, and thus considering one entry of without the other destroys this essential feature. Similarly, if one ignores safety and constructs a one-dimensional test of A1 = 0 versus A1 > 0 to achieve power .80 at 41.1 = .258 based on Y 1 alone, this requires only 2n = 94 patients. Thus, although it may be the case that one entry of a given target is a meaningful alternative to 0 in its one-dimensional subspace, this will not always be the case. The simplest illustration of this phenomenon is a target having one of its two entries equal to 0.
Comparison to One-Dzmensional Tests

Discussion
The primary goal of our proposed method is to construct comparative tests aimed at alternatives that explicitly quantify both efficacy and safety. We find this preferable t o the common practice of basing a formal test on efficacy alone while informally monitoring adverse events. The method relies on eliciting the two-dimensional target alternatives from the physician. We have found that oncologists are quite comfortable designing trials this way because it conforms quite naturally to their clinical perspective.
In rapidly fatal diseases, a central issue in specifying the targets is the extent to which failure to achieve the efficacy outcome is associated with early mortality. In acute leukemia, a patient who fails to achieve CR with the first treatment regimen is much less likely to achieve CR with a second treatment, and hence is more likely to die sooner. In other cancers, failure to achieve a response may not have such severe consequences in that a second round of treatment may be nearly as likely as the first to produce a remission. Thus, a higher risk of a severe adverse outcome is more likely to be considered an acceptable trade-off for a given improvement in efficacy in trials of rapidly fatal diseases. This general consideration will be reflected in the way the physician specifies the targets.
To apply the method in settings with nonnegative-valued outcomes Yi = ( Y , , , , y Z , 2 ) 
is the largest value such that P r { i E R I A = 0) 5 a. Although this construction is not possible for the ifosfamide trial, it may be applied to the alternatives in Designs 1, 2, or 4 of the gemcy trial, for which the respective sample sizes are 370, 444, and 252. Each of these values is larger than the corresponding value in Table 2 , although the difference is nontrivial only for Design 1, where an additional 36 patients would be required. A class of trade-off alternatives that cannot be accommodated by our procedure is illustrated by the following hypothetical case, suggested by a referee as a reasonable possibility that might arise in practice. Suppose that the clinician specifies the two target points ( 1 = (1,-2), an improvement of 1 unit in efficacy with a drop of 2 units in safety to achieve it, and (2 = (-1,2), an improvement of 2 units in safety with a drop of 1 unit in efficacy. Because the null hypothesis (0,O) is on the line connecting these two targets, i.e., on the boundary of the convex hull Clu of A((1) U A(&), it is impossible to construct the test. Similarly, the slight modification obtained by specifying (1 = (1,-2.1) produces an alternative hypothesis with (0,O) in its interior. A similar situation may arise if the clinician either has limited knowledge of the mechanism whereby T may provide an improvement over C or is simply being optimistic. In general, such settings may be accommodated by defining the alternative to be 0: = UF=(=l A(&) rather than the convex hull Ra of 0:. We have not examined the behavior of tests based on Rg here because we have not yet encountered an application of the type hypothesized above. However, if this second approach is used to construct an alternative 0: based on the three targets given in the case of Design 1 for the ifosfamide trial (Table 1) , then the resulting sample size would be 246, as compared with 226 when Cla is the alternative. Although the alternative certainly should include A(<) for each specified target (, whether the additional points contained in R,, but not in fig, should be included in the alternative is both a philosophical and a practical issue. The use of 0, is based on the belief that all convex combinations of desirable alternatives should also be included in the set of alternatives, whereas the use of 0: accommodates a broader class of problems.
Given that safety is an essential consideration, it follows that the trial design must accommodate situations where T either has unacceptably low efficacy or is unsafe compared with C. A group-sequential design with early termination and acceptance of the null hypothesis in either of these cases provides an additional level of safety. It may also be desirable to stop the trial early with the rejection of the null hypothesis when there is strong evidence that A E Ra. This motivates a group-sequential trial in which the three possible interim ity AT3 = -7 3 %Ll k,J log(2). decisions are to stop and reject R,, stop and accept R,, or continue to the next stage, with either acceptance or rejection of R, at the end. It seems reasonable that such a groupsequential version of the test may be constructed using the general theory of Jennison and Turnbull (1997) . We are currently developing a group-sequential version of the procedure.
As noted in the analysis of the gemcy trial design's sensitivity to $c, a more general approach to the bivariate binary case would be to specify the three-dimensional alternatives in terms of ( @ l , @ z , ~1 1 ) .
A simple way to do this would be to first construct the 2 x 2 table of null probabilities, then elicit the marginals of the target, and then ask the physician to specify how the four null probabilities should be adjusted to obtain the targeted marginals. This approach may prove useful in settings where a physician has a causal explanation for how a n experimental treatment should affect the four elementary outcome probabilities.
APPENDIX
For tivariate binary outcomes, denote Pr(Y,,1 = z and y2,2 = rz,io and 02,2 = Pr(Y,,2 = 1) = 7rZ,ll + 7rz,01, z = T , C .
For simplicity, temporarily suppress z and consider a single sample of n patients. Let W = (Woo, W~O , WOI, W~I )
be the multinomial vector corresponding to (7ro0, a l~, 7ro1, ~1 1 ) .
The y) = 7 r z~z y , z, y = 0,1, so that 0,,1 = Pr(Y,,1 = 1) = X , , l l + marginal efficacy and safety counts XI = W11 + Wio and X2 = W11 + Wol are binomial with parameters (n,&) and ( T I , & ) , respectively, and cov(X1, Xz) = n(7r117roo -~0 1 7 r i o ) .
The distribution of Y may be parameterized by the marginal probabilities 81,& and a third parameter accounting for association, which may be ~1 1 , a conditional probability such as 7 r 1 1 / O l r thecorrelation cor(Y1,Yz) = p = (7r11-016%)/{01(1-01)82(1 -02)}1/2 or the odds ratio $ = 7r117roo/7r1oxo1. An important special case is when the adverse and efficacy events cannot both occur, so that 7r1o = 0. It follows that 03. Thus, safety and efficacy are positively associated. The extreme case occurs when 7ro1 is also 0, equivalently 81 = 8-and p = 1, which is the binary case when safety and efficacy are the same event.
To apply the method in settings with nonnegative-valued outcomes, we apply the general theory developed by Wei and Lachin (1984) . For a J-variate vector of nonnegative-valued variables Y = (YI, . . . , YJ) subject to right censoring, Wei and Lachin (1984) constructed a J-variate statistic, which ma,y be used to construct a variety of two-sample tests. 
